Annual report pursuant to Section 13 and 15(d)

Fair Value Measurements (Narrative) (Details)

v3.22.1
Fair Value Measurements (Narrative) (Details)
 1 Months Ended 12 Months Ended
Nov. 16, 2021
$ / shares
shares
Oct. 06, 2021
USD ($)
Oct. 05, 2021
USD ($)
Sep. 30, 2021
USD ($)
Jun. 30, 2021
USD ($)
Mar. 31, 2021
USD ($)
Dec. 31, 2021
USD ($)
$ / shares
shares
Dec. 31, 2020
USD ($)
$ / shares
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Common stock, value             $ 101,000 $ 95,000
Caelum [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Fair value of investment               $ 17,600,000
Caelum [Member] | AstraZeneca [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Percentage of proceeds from option exercise     42.40% 42.40%        
Option exercise price     $ 150,000,000 $ 150,000,000        
Proceeds from option exercise     $ 56,900,000 $ 56,900,000        
Deconsolidation of consolidated partner company, upfront payment   $ 150,000,000            
Caelum [Member] | Share Price [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Investment, measurement input | $ / shares               2.43
Caelum [Member] | Risk Free Interest Rate [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Investment, measurement input               0.0036
Caelum [Member] | Expected Volatility [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Investment, measurement input               0.70
Caelum [Member] | Discount for Lack of Marketability [Member] | Minimum [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Investment, measurement input               0.210
Caelum [Member] | Discount for Lack of Marketability [Member] | Maximum [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Investment, measurement input               0.310
Journey [Member] | Dr. Reddy's Laboratories, Ltd [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Stock offering, price per share | $ / shares $ 9.1721              
Stock offering, number of shares issued | shares 545,131              
Journey [Member] | Dr. Reddy's Laboratories, Ltd [Member] | Contingent Conditions are Met [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Minimum market capitalization for contingent payment         $ 150,000,000      
Common stock, value         5,000,000.0      
Contingent cash payment         $ 5,000,000.0      
Journey [Member] | 8% Cumulative Convertible Class A Preferred Stock [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Stock offering, price per share | $ / shares             $ 10.00  
Stock offering, number of shares issued | shares             81,985  
Journey [Member] | 8% Cumulative Convertible Class A Preferred Stock [Member] | Preferred Stock has not been Converted into Journey Common Stock [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Preferred stock offering, aggregate proceeds           $ 25,000,000.0    
Journey [Member] | 8% Cumulative Convertible Class A Preferred Stock [Member] | Minimum [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Preferred stock offering, aggregate proceeds           12,500,000    
Journey [Member] | 8% Cumulative Convertible Class A Preferred Stock [Member] | Maximum [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Preferred stock offering, aggregate proceeds           $ 30,000,000.0    
Placement Agent Warrants [Member] | Journey [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Percentage of common stock for which the Preferred A is exchanged             5.00%  
Warrant expiration term             5 years  
Number of shares issued related to the conversion of warrants | shares             111,567